Payment overview · 2025
General Payments
$487.95
32 reported records · 5 companies
Healthcare provider profile · identity verified
Mark J Korte, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HERRIN, IL · NPI 1821102849
Verified facts
What the public records show
CMS Open Payments records show Mark J Korte, M.D. received $487.95 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 73.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $356.31 | 73.0% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.76 | 10.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.86 | 6.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.15 | 5.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.87 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $487.95 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $356.31 | 24 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.15 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
191 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 644 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 143 |
| Lisinopril | Lisinopril | 441 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 440 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 422 | 101 |
| Gabapentin | Gabapentin | 413 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 80 |
| Alprazolam | Alprazolam | 345 | 86 |
| Omeprazole | Omeprazole | 329 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 318 | 73 |
| Furosemide | Furosemide | 288 | 69 |
| Meloxicam | Meloxicam | 287 | 61 |
| Metformin Hcl | Metformin Hcl | 286 | 66 |
| Glipizide | Glipizide | 285 | 56 |
| Montelukast Sodium | Montelukast Sodium | 284 | 48 |
| Irbesartan | Irbesartan | 281 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 274 | 43 |
| Carvedilol | Carvedilol | 271 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 248 | 58 |
| Potassium Chloride | Potassium Chloride | 247 | 46 |
| Simvastatin | Simvastatin | 221 | 49 |
| Famotidine | Famotidine | 218 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 217 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 217 | 39 |
| Losartan Potassium | Losartan Potassium | 212 | 41 |
| Sertraline Hcl | Sertraline Hcl | 209 | 34 |
| Eliquis | Apixaban | 191 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 45 |
| Olanzapine | Olanzapine | 157 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 157 | 38 |
| Risperidone | Risperidone | 155 | suppressed |
| Lorazepam | Lorazepam | 148 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 145 | 21 |
| Atenolol | Atenolol | 143 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 22 |
| Jardiance | Empagliflozin | 123 | 30 |
| Prednisone | Prednisone | 121 | 68 |
| Ozempic | Semaglutide | 120 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 37 |
| Farxiga | Dapagliflozin Propanediol | 116 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 112 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 110 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 31 |
| Warfarin Sodium | Warfarin Sodium | 105 | 18 |
| Spironolactone | Spironolactone | 103 | 27 |
| Clonazepam | Clonazepam | 102 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 16 |
| Allopurinol | Allopurinol | 95 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 20 |
| Sucralfate | Sucralfate | 89 | suppressed |
| Azithromycin | Azithromycin | 87 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 17 |
| Diazepam | Diazepam | 86 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 24 |
| Temazepam | Temazepam | 82 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | suppressed |
| Levetiracetam | Levetiracetam | 79 | suppressed |
| Pregabalin | Pregabalin | 77 | 16 |
| Buspirone Hcl | Buspirone Hcl | 75 | 20 |
| Ezetimibe | Ezetimibe | 74 | 13 |
| Mirtazapine | Mirtazapine | 74 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 14 |
| Lamotrigine | Lamotrigine | 71 | suppressed |
| Celecoxib | Celecoxib | 68 | 23 |
| Divalproex Sodium | Divalproex Sodium | 68 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 68 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 29 |
| Eszopiclone | Eszopiclone | 64 | 12 |
| Synthroid | Levothyroxine Sodium | 64 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 63 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | suppressed |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 59 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 27 |
| Nabumetone | Nabumetone | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Dutasteride | Dutasteride | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 50 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 12 |
| Valproic Acid | Valproic Acid | 48 | suppressed |
| Baclofen | Baclofen | 47 | 14 |
| Ketoconazole | Ketoconazole | 46 | 20 |
| Lovastatin | Lovastatin | 46 | 12 |
| Nifedipine Er | Nifedipine | 46 | 11 |
| Chlorthalidone | Chlorthalidone | 44 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 18 |
| Fenofibrate | Fenofibrate | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Linzess | Linaclotide | 44 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 43 | suppressed |
| Fluconazole | Fluconazole | 42 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | 14 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 14 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Piroxicam | Piroxicam | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxaprozin | Oxaprozin | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 11 |
| Torsemide | Torsemide | 13 | suppressed |
| Altavera | Levonorgestrel/Ethin.Estradiol | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.95 · 32 records | ABBVIE INC. | ABRYSVO, COMIRNATY, Ozempic, PREVNAR 20, Rybelsus, TRINTELLIX, VOQUEZNA, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error